| scholarly article | Q13442814 |
| P2093 | author name string | Kathleen A Snella | |
| Kelly A Cochran | |||
| Daniel S Aistrope | |||
| Lauren E Odum | |||
| P2860 | cites work | Development of a Contemporary Bleeding Risk Model for Elderly Warfarin Recipients | Q58464315 |
| Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin | Q28171104 | ||
| A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO) | Q28212894 | ||
| Independent predictors of stroke in patients with atrial fibrillation: a systematic review | Q28219197 | ||
| Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial | Q28219363 | ||
| 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines | Q28305368 | ||
| Validation of Clinical Classification Schemes for Predicting Stroke | Q29028208 | ||
| Atrial fibrillation as an independent risk factor for stroke: the Framingham Study | Q29614200 | ||
| Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators | Q33863941 | ||
| A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice | Q34146593 | ||
| Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly | Q34152050 | ||
| A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study | Q34225539 | ||
| Evaluating the yield of medical tests | Q34277948 | ||
| Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study | Q34540479 | ||
| Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). | Q34788530 | ||
| Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation | Q35003773 | ||
| Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review. | Q35016262 | ||
| Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study | Q36255692 | ||
| Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation | Q37141681 | ||
| The net clinical benefit of warfarin anticoagulation in atrial fibrillation | Q37421352 | ||
| Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis | Q37784893 | ||
| Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter | Q37844248 | ||
| Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population | Q39854204 | ||
| Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke | Q40228075 | ||
| Comparison of outcomes of patients with symptomatic peripheral artery disease with and without atrial fibrillation (the West Birmingham Atrial Fibrillation Project). | Q42030628 | ||
| Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort | Q42850914 | ||
| Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). | Q42923039 | ||
| Risk stratification and therapeutic decision making in acute coronary syndromes | Q43679953 | ||
| Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). | Q43840992 | ||
| Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial | Q44672192 | ||
| Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial | Q45258336 | ||
| Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators | Q46139300 | ||
| Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. | Q50234449 | ||
| Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. | Q51768133 | ||
| Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring | Q56985699 | ||
| 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation | Q56986288 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atrial fibrillation | Q815819 |
| P304 | page(s) | 285-296 | |
| P577 | publication date | 2012-03-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | The CHADS₂versus the new CHA2DS2-VASc scoring systems for guiding antithrombotic treatment of patients with atrial fibrillation: review of the literature and recommendations for use. | |
| P478 | volume | 32 |
| Q36618123 | A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. |
| Q36277366 | Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS2 and CHA2DS2-VASc score levels and warfarin prescription for adult patients with atrial fibrillation |
| Q38081257 | Antithrombotics for stroke prevention in non-valvular atrial fibrillation: an update |
| Q38804112 | Atrial Fibrillation Genetics: Is There a Practical Clinical Value Now or in the Future? |
| Q38095871 | Clinical update on the management of atrial fibrillation. |
| Q38014343 | Dabigatran and left atrial appendage thrombus. |
| Q38682105 | Inpatient Mortality Risk Scores and Postdischarge Events in Hospitalized Heart Failure Patients: A Community-Based Study |
| Q36395780 | Net Clinical Benefits of Guidelines and Decision Tool Recommendations for Oral Anticoagulant Use among Patients with Atrial Fibrillation |
| Q47336250 | Oral anticoagulation therapy upon discharge in hospitalized patients with nonvalvular atrial fibrillation: a retrospective cohort study. |
| Q48063492 | Relevance of depression for anticoagulation management in a routine medical care setting: results from the ThrombEVAL study program |
| Q99578858 | Self-reported risk of stroke and factors associated with underestimation of stroke risk among older adults with atrial fibrillation: the SAGE-AF study |
| Q36458805 | Stroke Prevention in Atrial Fibrillation - Outcomes and Future Directions |
| Q38728028 | Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices? |
| Q37226300 | Suboptimal use of non-vitamin K antagonist oral anticoagulants: Results from the RAMSES study |
| Q35040744 | Vascular risk factors and clinical progression in spinocerebellar ataxias |
Search more.